. Author manuscript; available in PMC: 2009 Oct 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2008 Oct;14(10):1088–1099. doi: 10.1016/j.bbmt.2008.08.001

Table I.

IL-2 therapy combined with CD25 depletion promotes survival mediated by NK1.1+, but not CD8+ cells¹.

Treatment	Mice Surviving on Day 35	Mean Survival Time (Mean ± SEM)
Control (no treatment)	0/16	27.1 ± 0.73
rhIL-2 + anti-CD25	8/16^*	39.2 ± 3.4^**
NK1.1 Depletion	0/16	25.0 ± 0.78
NK1.1 Depletion + rhIL-2 + anti-CD25	0/16	25.8 ± 0.73
CD8 Depletion	0/16	29.1 ± 0.75
CD8 Depletion + rhIL-2 + anti-CD25	8/16^*	43.8 ± 4.9^**

Mice were injected with 2×10⁵ C1498 cells, i.v., on day 0. Mice were either injected with PBS/rIgG controls (Group 1), with rhIL-2 (2×10⁵ IU, days 1, 3, 5, 7) and anti-CD25 antibodies (1mg, day 1, 4, 7)(Group 2), with PK136 (500ug, day 1, 5; Group 3), with IL-2 and anti-CD25 as above plus PK136 (Group 4), with anti-CD8 (300ug, day 1, 5; Group 5) or with IL-2 and anti-CD25 combined with anti-CD8 (Group 6).

P<0.01 by two-tailed Fisher Exact Test compared to specific no treatment controls.

^**

P<0.01 by Oneway ANOVA with Tukey multiple comparison test compared to specific no treatment controls.